Examining the Injustices in Pharmaceutical Investments and Judicial Legitimacy

This chapter examines the shortcomings of American taxpayer investments in pharmaceutical companies, particularly the absence of affordable medication as a return. It also discusses the implications of a judicial ruling on the abortion pill mifepristone and the potential consequences of defying court decisions for judicial legitimacy.